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OBJECTIVES We sought to identify the triggers of ventricular tachyarrhythmia (VTA) in experimental
models of long QT type 2 (LQT2) and long QT type 3 (LQT3) syndromes.
BACKGROUND Most adverse cardiac events occurring in the long QT type 1 syndrome are related to
sympathetic nerve activity. In contrast, various factors may trigger VTA in patients with
LQT2 and LQT3.
METHODS The mode of onset of VTA and therapeutic effects of the potassium-adenosine triphosphate
channel opener nicorandil were compared in canine models of LQT2 and LQT3, using three
induction protocols: 1) bradycardia produced by atrioventricular block (BRADY); 2)
programmed ventricular stimulation; and 3) electrical stimulation of the left stellate ganglion
(left stellate stimulation [LSS]). Transmural unipolar electrograms were recorded, and the
activation-recovery interval (ARI) was measured.
RESULTS Ventricular tachyarrhythmias developed during BRADY in all six experiments in the LQT3
model, but in none of the six experiments in LQT2. Programmed ventricular stimulation
induced VTA in two experiments of the LQT2 model, but in none of the LQT3 experiments.
Stimulation of the left stellate ganglion induced VTA in three experiments in LQT2 and in
two experiments in LQT3. Nicorandil caused greater shortening of ARI and greater
attenuation of transmural ARI dispersion in the LQT2 model than in the LQT3 model.
After treatment with nicorandil, a single VTA was induced in the LQT2 model by LSS,
whereas in the LQT3 model, VTA remained inducible by BRADY in four experiments and
LSS in one experiment.
CONCLUSIONS An abrupt increase in sympathetic activity appeared arrhythmogenic in both models.
Nicorandil attenuated the heterogeneity of ventricular repolarization and suppressed the
induction of VTA in the LQT2 model, but had a limited therapeutic effect in the LQT3
model. (J Am Coll Cardiol 2002;40:555–62) © 2002 by the American College of
Cardiology Foundation
Recent genetic and molecular studies have shown that some
inheritable rhythm disturbances may be caused by geneti-
cally determined myocardial ion channel abnormalities
(1,2). Thus far, particularly detailed analyses have been
carried out in congenital long QT syndrome (LQTS), with
six subtypes identified in Romano-Ward syndrome and two
in Jervell-Nielsen syndrome (3). Because LQTS is classified
on the basis of abnormalities in the gene of myocardial ion
channels, the mode of onset of ventricular tachyarrhythmia
(VTA) and therapeutic effects of some interventions may
vary among subtypes of the syndrome (4,5). Most adverse
cardiac events occurring in long QT type 1 syndrome
(LQT1) are related to sympathetic nerve activity and are
effectively prevented by beta-adrenergic blockade (6,7). In
contrast, a number of factors may trigger VTA in patients
with LQT2 and LQT3 (6).
To determine the modes of onset of VTA in LQT2 and
LQT3, the inducibility of VTA by three different induction
protocols was compared in canine models of LQT2 and
LQT3: 1) bradycardia caused by atrioventricular block
(BRADY); 2) programmed ventricular stimulation (PVS);
and 3) electrical stimulation of the left stellate ganglion (left
stellate stimulation [LSS]). The therapeutic effects of the
potassium-adenosine triphosphate (K-ATP) opener nic-
orandil were also examined.
METHODS
Surgical preparation. The present study was approved by
the Animal Studies Subcommittee of our Institutional
Review Board. Experiments were performed on twelve 24-
to 36-week-old beagles. The dogs were anesthetized with
sodium thiopental (17.5 mg/kg intravenous bolus, followed
by a maintenance dose of 5.0 mg/kg per h), intubated and
ventilated with an animal respirator. Catheters were inserted
into the femoral vein for administration of fluids and drugs
and into the femoral artery to monitor blood pressure.
Electrocardiographic leads I, II and aVF and blood pressure
were continuously monitored. The heart was exposed
through a midline sternotomy. A core temperature was
maintained constant at 37°C with a thermostatically con-
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trolled thermal blanket. Saline warmed to 37°C was regu-
larly applied to the heart to moisten and prevent cooling of
the epicardial surface. Bradycardia produced by atrioventric-
ular block was accomplished by radiofrequency catheter
ablation of the atrioventricular junction, and right ventric-
ular pacing was performed through endocardial bipolar
stainless-wire electrodes. Electrical LSS was performed by
the delivery of square pulses (duration of 2 ms, output of 5.0
V and frequency of 10 Hz) through a 75-m polymide-
coated silver wire denuded over 2 to 3 mm at its tip and
inserted into the surgically exposed ganglion. Upon com-
pletion of the experiment, ventricular fibrillation was in-
duced electrically and the heart was excised.
Recording and pacing electrodes. Four plunge-needle
electrodes were inserted in the mid left ventricular myocar-
dium, where prominent M-cell–like activity has been found
in canine experimental models (8,9). The needle electrodes
were made of polymide-coated tungsten wires, 50 m in
diameter, containing a 21-gauge stainless-steel needle. Each
needle supported eight unipolar electrodes 1 mm apart. The
most proximal electrode was located 0.5 mm from the
epicardial surface, and unipolar electrograms across the left
ventricular walls from the epicardial, mid-myocardial and
endocardial sites were recorded simultaneously (8,9). The
heart was paced from bipolar electrodes inserted in the right
ventricular endocardial site. Pacing pulses 2 ms in duration
were delivered by a programmable cardiac stimulator at
twice the end-diastolic threshold.
Data acquisition. Each electrogram was amplified and
filtered at a fixed high-pass setting of 0.05 Hz and adjust-
able low-pass setting of 500 Hz. Analog data were digitized
at a sampling rate of 1,000 Hz (MacLab System, AD
Instruments, NSW, Australia). To estimate local refracto-
riness, the activation-recovery interval (ARI) was calculated
from each unipolar electrogram (10). Activation-recovery
interval was defined as the interval between the time of the
minimal first derivative of the intrinsic deflection of the
QRS complex and the maximal first derivative of the
T-wave on the unipolar electrogram (10,11).
Drug administration. In six dogs, LQT2 was simulated
with dofetilide dissolved in sterile saline administered as a
20 g/kg intravenous bolus, followed by a maintenance dose
of 0.1 g/kg/min. In six other dogs, LQT3 was simulated
with anthopleurin-A dissolved in sterile saline administered
as a 5 g/kg intravenous bolus, followed by a maintenance
dose of 0.2 g/kg/min. Nicorandil was dissolved in sterile
saline and administered intravenously at a rate of 0.2
mg/kg/3 min.
Study protocol. INDUCTION OF VTA. In both LQTS mod-
els, three protocols were used to study the inducibility of
VTA before and after the administration of nicorandil: 1)
bradycardia was produced by radiofrequency ablation of the
atrioventricular node, followed by a slow ventricular escape
rhythm and back-up demand pacing at an escape interval of
1,500 ms continued for 10 min; 2) PVS with two or three
extrastimuli was attempted from the right ventricle during
pacing at 600-ms and 400-ms basic cycle lengths (BCLs); 3)
sympathetic stimulation was performed for 30 s by LSS
Figure 1. Inducibility of ventricular tachyarrhythmia before and after administration of nicorandil. Each bar represents the number of experiments during
which ventricular tachyarrhythmias were induced. BRADY  bradycardia produced by atrioventricular block; LQT2 and LQT3  long QT syndrome,
types 2 and 3, respectively; LSS  left stellate (ganglion) stimulation; PVS  programmed ventricular stimulation.
Abbreviations and Acronyms
ARI  activation-recovery interval
BCL  basic cycle length
BRADY  bradycardia produced by atrioventricular
block
K-ATP  potassium-adenosine triphosphate
LSS  left stellate (ganglion) stimulation
LQTS  long QT syndrome
LQT1  long QT type 1 syndrome
LQT2  long QT type 2 syndrome
LQT3  long QT type 3 syndrome
PVS  programmed ventricular stimulation
VTA  ventricular tachyarrhythmia
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during ventricular pacing at 600 ms BCL. When sustained
VTA was induced, 5- to 20-J defibrillation shocks were
delivered and at least 10 min was allowed to elapse after the
shock before continuation of the protocol.
DISTRIBUTION AND TRANSMURAL DISPERSION OF ARI. The
ARI at each layer of the ventricle and transmural ARI
dispersion were analyzed at 600-ms and 400-ms BCL
pacing before administration of nicorandil and at 600-ms
BCL pacing after nicorandil. The most proximal and distal
plunge electrode sites were used as representatives of the
epicardial and endocardial layers, respectively, whereas an
intermediate site with the longest ARI at baseline was used
a representative of the mid-myocardial site layer. Transmu-
ral ARI dispersion was defined as the maximal ARI differ-
ence at each needle electrode. An average ARI value was
calculated from three consecutive beats at each experimental
phase. The beat-to-beat ARI difference was consistently
10 ms during each pacing protocol.
Statistical analysis. Statistical analysis was performed by
using the Student t test, analysis of variance and Scheffe´
multiple-range post-hoc test, as appropriate. A p value
0.05 was considered statistically significant. Data are
presented as the mean value  SD.
RESULTS
Induction of VTA and effects of nicorandil. During
simulated LQT2 syndrome, VTA did not develop during
bradycardia in any of the six experiments (Fig. 1). In
contrast, PVS induced VTA in two experiments, and LSS
induced VTA in three experiments (Fig. 2A). Administra-
tion of nicorandil was followed by a nonstatistically signif-
icant decrease in systolic and diastolic blood pressure from
120  14 mm to 109  11 mm Hg and 65  6 mm Hg to
60 8 mm Hg, respectively, during pacing at 600 ms BCL.
After the administration of nicorandil, VTA was induced by
neither BRADY nor PVS, although it remained inducible
by LSS in one experiment. During simulated LQT3 syn-
drome, spontaneous VTA developed during BRADY in all
six experiments (Fig. 2C). In contrast, PVS failed to induce
VTA. Stimulation of the left stellate ganglion induced VTA
in two experiments. After treatment with nicorandil, spon-
taneous VTA developed during BRADY in three experi-
Figure 2. Induction of ventricular tachyarrhythmias (VTAs) in the long QT syndrome type 2 (LQT2) (A) and long QT syndrome type 3 (LQT3) (B and
C) models. During 600-ms basic cycle length pacing, VTA was initiated by a premature beat during left stellate (ganglion) stimulation (LSS) in LQT2
(A). In the LQT3 model, LSS induced multiple premature ventricular complexes and initiated VTA (B). (C) Bradycardia produced by atrioventricular
block-dependent VTA. A premature ventricular beat (#) infringed on spatial dispersion of repolarization and created functional conduction block or delayed
conduction at the mid-myocardial site (Mid). Endo  endocardial site; Epi  epicardial site.
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ments. In one other experiment, VTA was induced by both
LSS and BRADY.
In no experiment did previously noninducible VTA
become inducible after the administration of nicorandil.
In both LQTS models, initiation of VTA was associated
with the development of conduction block or delayed
conduction at the mid-myocardial and endocardial sites,
with prolonged ARI at baseline. In all 10 episodes of
BRADY-related VTA in the LQT3 model, a short-long-
short cardiac sequence or ARI alternans associated with
premature ventricular beats (Fig. 2C) was observed before
the development of VTA. Among seven episodes of LSS-
induced VTA, VTA was initiated after a short-long-short
cardiac sequence in five episodes (3 in the LQT2 model and
2 in the LQT3 model) (Fig. 2A), and repetitive premature
ventricular beats triggered VTA in two other episodes (one
in the LQT2 model and one in the LQT3 model) (Fig. 2B).
The ARI and its transmural dispersion in each model of
LQTS. Figure 3 illustrates unipolar recordings from a
needle electrode placed in the mid left ventricular myocar-
dium in the LQT2 model. At 600-ms BCL pacing, ARI at
the mid-myocardial site was longer than that at the epicar-
dial and endocardial sites, resulting in transmural ARI
dispersion of 43 to 44 ms in this area. When the BCL was
shortened to 400 ms, the ARIs at all sites were shortened
significantly (Table 1), and transmural ARI dispersion
decreased to 30 to 31 ms as a result of greater ARI
shortening at the mid-myocardial site than at the epicardial
site (Table 2). The intravenous administration of nicorandil
also shortened the ARIs in all three layers of the ventricle at
a drive BCL of 600 ms (Table 1) and decreased ARI
dispersion to 25 to 26 ms. The ARIs at 400-ms BCL pacing
were statistically longer than those at 600 ms after nicoran-
dil in all three layers of the ventricle (Table 1). In each
pacing condition, the ARIs at the mid-myocardial and
endocardial sites were statistically longer than those at the
epicardial site. Compared with 600-ms BCL pacing before
the administration of nicorandil, transmural ARI dispersion
was markedly attenuated by both 400-ms BCL pacing and
infusion of nicorandil, and transmural ARI dispersion was
not significantly different between 400-ms BCL pacing
before nicorandil (27.8  7.7 ms) and 600-ms BCL pacing
after nicorandil (22.3  6.7 ms) (Fig. 4).
Figure 5 shows the same analysis in the LQT3 model and
presents unipolar electrograms recorded from a needle
electrode in the left ventricle. During 600-ms BCL pacing,
ARI at the mid-myocardial site was longer than that at the
epicardial and endocardial sites, resulting in marked trans-
mural ARI dispersion of 69 ms. When the pacing BCL was
shortened to 400 ms, the ARIs were abbreviated in all three
layers of the ventricle (Table 1), but shortening of ARI was
considerably greater at the mid-myocardial site than at the
epicardial and endocardial sites, and transmural ARI dis-
persion decreased to 30 to 33 ms. The intravenous admin-
istration of nicorandil also shortened ARI, although the
effect was weak, resulting in transmural dispersion of 54 to
56 ms. During 600-ms BCL pacing before and after
nicorandil administration, ARI at the mid-myocardial site
was longer than that at the epicardial site. In contrast, each
layer of the ventricle showed similar ARI values during
Figure 3. Transmural unipolar recording of the left ventricle in the long QT syndrome type 2 (LQT2) model. The activation-recovery interval (ARI) and
its transmural dispersion are presented during pacing at basic cycle lengths (BCLs) of 600 ms (A), 400 ms (B) and 600 ms after nicorandil (C). The ARI
measurements are shown with each electrogram. The thin vertical line in each electrogram represents the point of the maximal derivative of the T-wave.
(A) The mid-myocardial (Mid) site shows greater ARI prolongation than the epicardial (Epi) or endocardial (Endo) sites, resulting in a 43- to 44-ms ARI
dispersion across the ventricular wall. Faster pacing at a 400-ms BCL shortened ARI at all sites, and transmural ARI dispersion was reduced to 30 to 31
ms (B). Compared with faster pacing, the magnitude of ARI shortening was significantly greater when nicorandil was administrated during 600-ms BCL
pacing, and transmural ARI dispersion decreased to 25 to 26 ms (C).
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pacing at 400 ms before the administration of nicorandil
(Table 1). In all myocardial layers, ARI was shorter during
400-ms BCL pacing before the administration of nicorandil
than at 600 ms after nicorandil administration (Table 1).
Before nicorandil, transmural ARI dispersion during
400-ms BCL pacing (21.4  9.0 ms) was significantly less
than that at 600 ms (51.2 17.5 ms), although there was no
statistically significant difference in transmural ARI disper-
sion between 600-ms BCL pacing before (51.2  17.5 ms)
and after (42.3  12.9 ms) nicorandil infusion (Fig. 4).
Finally, transmural ARI dispersion was less during 400-ms
BCL pacing before nicorandil administration than during
600-ms BCL pacing after nicorandil administration.
Comparison of ARI and its transmural dispersion be-
tween the LQT2 and LQT3 models. During 600-ms
BCL pacing before and after nicorandil, the ARIs in the
LQT3 model were longer than those in the LQT2 model in
all three layers of the ventricle (Table 1). In contrast, the
ARIs in all three layers of the ventricle in the LQT2 model
became longer than those in the LQT3 model during
400-ms BCL pacing before nicorandil. Transmural ARI
dispersion in the LQT3 model was greater than that in the
LQT2 model at 600-ms BCL pacing before and after
nicorandil, whereas transmural ARI dispersion in the
LQT2 model was larger than that in the LQT3 model
during 400-ms BCL pacing before administration of nic-
orandil (Fig. 4). Compared with LQT3, the percentage of
ARI shortening by nicorandil was significantly greater in
the LQT2 model in all three myocardial layers (Table 2).
However, pacing at the shorter BCL of 400 ms was
associated with a greater percent shortening of ARI in all
myocardial layers in the LQT3 model.
DISCUSSION
Modes of VTA induction. Recent studies have shown that
most cardiac events in LQT1 are triggered by sympathetic
activity associated with exercise in 62% of patients and
emotional stress in 26% (6). In LQT2 syndrome, adverse
events have been associated with exercise in 13% of patients,
emotional stress in 43% and sleep in 15%; in LQT3, with
exercise in 13%, emotional stress in 19% and sleep in 39%.
In our canine LQT3 model, the onset of spontaneous VTA
was bradycardia-dependent in all six experiments, an obser-
vation consistent with previous studies (12,13). Bradycardia
produced by atrioventricular block induced marked ARI
prolongation at the mid-myocardial site and increased
transmural dispersion of repolarization. A short-long-short
cardiac sequence and/or ARI alternans associated with
premature ventricular beats would facilitate ARI prolonga-
tion and enlargement of transmural dispersion of repolar-
ization and could trigger VTA (Fig. 2) (14). In contrast, the
onset of VTA was not provoked by BRADY in the LQT2
model (Fig. 1). However, ARI prolongation and transmural
ARI dispersion were not as prominent in the LQT2 model
than in the LQT3 model during slow heart rates (Fig. 3 andTa
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5). The ARIs in all three layers of the ventricle in the LQT2
model were statistically shorter than those in the LQT3
model during 600-ms BCL pacing (Table 1). Pharmaco-
logic blockade of Ikr channels is usually unsuccessful in
prolonging the action potential duration to the extent
observed in human LQT2 syndrome (13,15,16), and this
limitation may have prevented the development of
BRADY-dependent VTA in our LQT2 model.
Ventricular tachyarrhythmias were not reliably induced
by PVS in the LQT2 or LQT3 model. These results are
consistent with the known lack of success of PVS in
reproducing VTA during electrophysiologic testing in pa-
tients with LQTS, because the first premature stimulus at
an intermediate coupling interval or the basic stimulation
train, or both, tend to decrease the degree of transmural
dispersion of repolarization (9). The total inducibility of
Table 2. Percent Shortening of the Activation–Recovery Interval by Faster Pacing and Nicorandil Administration
Endo (%) Mid (%) Epi (%) ANOVA
Faster pacing (BCL 400 ms) p  0.135 p  0.04
ÈÈ
LQT2 (n  24, 6 exp.  4 needles) 16.9  2.7 17.9  2.8 16.2  1.0 p  0.04
Ç
p  0.268
p  0.043 p  0.0001
ÈÈ
LQT3 (n  24, 6 exp.  4 needles) 31.2  2.5 33.5  3.7 28.8  5.0 p  0.0004
p  0.034
Comparison between LQT2 and LQT3 p  0.0001 p  0.0001 p  0.0001
Nicorandil (BCL 600 ms) p  0.001 p  0.0001
ÈÈ
LQT2 21.8  2.1 23.3  1.9 19.8  1.9 p  0.0001
Ç
p  0.001
p  0.239 p  0.0001
ÈÈ
LQT3 8.8  2.0 9.6  1.2 6.1  3.5 p  0.0001
p  0.0004
Comparison between LQT2 and LQT3 p  0.0001 p  0.0001 p  0.0001
Data are presented as the mean value  SD.
ANOVA  analysis of variance; BCL  basic cycle length; other abbreviations as in Table 1.
Figure 4. Mean transmural activation-recovery interval (ARI) dispersion in the long QT syndrome type 2 (LQT2) and long QT syndrome type 3 (LQT3)
models. See text for details. N.S.  not significant.
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VTA by PVS in the LQT3 model is probably attributable to
the adaptive shortening of ARI in response to rapid pacing,
which was greater in the LQT3 model than in the LQT2
model (Figs. 3 and 5, Table 2) (15,16).
It is noteworthy that sympathetic stimulation triggered
VTA in three simulated LQT2 and two simulated LQT3
experiments. These results are consistent with the precipi-
tation of adverse cardiac events by exercise or emotional
stress in both LQT2 and LQT3 syndromes (6). In contrast,
sustained beta-adrenergic stimulation has been found to
decrease transmural dispersion of repolarization and to
suppress VTA in LQT2 and LQT3 experimental models
(15,16). Despite this apparently protective effect, the mul-
tiple premature beats observed immediately after the onset
of LSS may occur at a time when prominent spatial
dispersion of repolarization is still present. The results of
these LSS experiments suggest that an abrupt increase in
sympathetic activity and associated premature beats were
arrhythmogenic in both models. Furthermore, in addition
to a short-long-short cardiac sequence, repetitive premature
ventricular beats triggered VTA in two episodes of LSS-
associated VTA (Fig. 2B). The initiation pattern of LSS-
induced VTA may be different between the LQT2 and
LQT3 models, but this could not be clarified because of the
small number of experiments and VTA episodes in the
present study.
Antiarrhythmic effect of nicorandil. The therapeutic ef-
fects of nicorandil in patients with LQT1 have recently been
reported (17). In addition, nicorandil was more effective in
the LQT1 and LQT2 models than in the LQT3 model
(18). The results of this study are consistent with these
clinical and experimental studies—in particular, the greater
abbreviation of ARI and larger reduction of transmural ARI
dispersion by nicorandil in the LQT2 model than in the
LQT3 model. The precise mechanisms of the different
response to nicorandil in the two LQTS models have not
been clarified. A reduced Ikr during phase 3 of the action
potential may increase myocardial membrane resistance, and
additional currents through K-ATP channels may easily
modulate the membrane potential (18). Conversely, an
increase in late sodium current can be associated with a
smaller membrane resistance in the LQT3 model, and a
further net increase in the outward current through the
K-ATP channels may have a small effect on the plateau of
the action potential. The same hypothesis may be advanced
to explain the greater ARI shortening at the mid-
myocardial site as compared with the epicardial and endo-
cardial sites (Table 2). The M-cell–like myocardium is
characterized by reduced Iks currents, whereas the late
sodium current and sodium-calcium exchange current are
believed to be increased (19).
Clinical implications. As in LQT1 syndrome, an abrupt
increase in sympathetic nerve activity appears arrhythmo-
genic in LQT2 and LQT3, which may explain the thera-
peutic effects of beta-blockade in all three subtypes (7). In
our experiments, the effect of nicorandil in the LQT2 and
LQT3 models was different, although it was antiarrhythmic
in both models. Therefore, nicorandil may represent an-
other therapeutic option in LQTS.
Study limitations. Sympathetic nerve stimulation was lim-
ited to LSS, and the output was fixed at 5 V. This choice
was based on the apparent exaggerated and unbalanced
Figure 5. Transmural unipolar recordings of the left ventricle in the long QT syndrome type 3 (LQT3) model, as presented in Figure 3. (A) Pacing at
600-ms basic cycle length (BCL). The activation-recovery interval (ARI) at the mid-myocardial (Mid) site was longer than that at the epicardial (Epi) and
endocardial (Endo) sites, and marked ARI dispersion of 69 ms was observed across the ventricular wall. Faster pacing at 400-ms BCL (B) shortened ARI
at all sites, and transmural ARI dispersion was decreased to 30 to 33 ms. Intravenous administration of nicorandil slightly shortened all ARIs at 600-ms
BCL pacing (C), and prominent transmural ARI dispersion of 54 to 56 ms persisted across the ventricular wall.
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left-sided sympathetic activity associated with arrhythmo-
genesis in patients with LQTS (20). Further studies includ-
ing stimulation of the right stellate ganglion are required to
further our understanding of sympathetic activity as an
arrhythmogenic factor in LQTS.
The needle electrodes were inserted into the mid left
ventricular myocardium, which, in this canine model, ex-
hibited prominent M-cell–like behavior. However, the dis-
tribution of M-cell–like activity is heterogeneous (9), such
that the limited number of recording electrodes may have
underestimated the heterogeneity of ventricular repolariza-
tion.
The effects of nicorandil were studied after a single dose.
Different doses of nicorandil may have different effects on
VTA inducibility and transmural ARI dispersion in these
experimental models. Several mutations have been reported
in the HERG and SCN5A genes, and the clinical charac-
teristics of LQTS vary depending on each mutation (21,22).
Therefore, experimental studies of drug efficacy using these
models are limited in their ability to test the clinical
usefulness of therapeutic interventions.
Nicorandil reduced the duration and transmural disper-
sion of ARI, and its effects were more prominent in the
LQT2 model than in the LQT3 model. However, nicoran-
dil produced conflicting results on the induction of VTA,
and convincing evidence on nicorandil’s protective effect on
the inducibility of VTA in the LQT2 versus LQT3 model
was not provided because of the small number of experi-
ments in the present study. Further studies with a larger
study group are required for detailed analysis of different
initiation modes of VTA and the therapeutic effect of
nicorandil in the LQT2 and LQT3 models.
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